Login to Your Account

Lemtrada Hits Endpoint in Phase III; Don't Count CVRs Yet

By Jennifer Boggs

Tuesday, July 12, 2011
The good news is that Lemtrada (alemtuzumab), the hotly contested drug at the center of negotiations in Sanofi SA's buyout of Genzyme Corp. earlier this year, hit its primary endpoint in the first Phase III study in multiple sclerosis (MS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription